MP Biomedicals, LLC has recently expanded its portfolio of COVID-19-related research products to include a wide selection of highly pure SARS-CoV-2 recombinant proteins, monoclonal antibodies specific and potent against a variety of SARS-CoV-2 protein domains, and high-quality ELISA kits to quantify SARS-CoV-2 and the virus-triggered human IgM and IgG antibodies.
The disease COVID-19, caused by SARS-CoV-2 virus infection, continues to impact public health on a global scale. With new variants rapidly emerging, it is critical that scientists have access to the latest research tools. MP Biomedicals’ extensive line of SARS-CoV-2 research products are fully validated to ensure quality and performance to help advance COVID-19 research.
“Our new collection of COVID-19-related research products is another big step towards our goal of providing researchers with innovative, quality solutions,” said Dr. Xiao-wei Wang, Immunology Product Manager, MP Biomedicals. “We will continue to expand our portfolio and offerings to do our part in addressing the current needs of the scientific community.”
To learn more about MP Biomedicals’ COVID-19 research products, please visit www.mpbio.com/sars-cov-2-research.
